Aug 19, 2021

What is the value of managing drug trend across both the pharmacy and medical benefit?

As a PBM, IngenioRx highlights their approach and the value of integrated management in their 2020 Trend Report and Specialty Supplement.

Aug 19, 2021

ESI National Preferred Formulary Exclusion Changes

Impossible to exclude life-saving orphan drugs from formularies? Not anymore. ESI says “no” to Pfizer’s and Takeda’s Gaucher disease agents in favor of Sanofi-Genzyme’s.

Aug 19, 2021

Survey Results: What (if any) drug pricing reform is likely to come in the next few years?

Aug 19, 2021

The FDA approval of Mylan’s Semglee as an “interchangeable biosimilar,” for Lantus will allow pharmacies to substitute Semglee for Lantus like any generic drug (subject to state pharmacy laws).

How long until we see typical generic substitution and generic dispensing rates in the insulin glargine market?

Aug 19, 2021

Survey: What (if any) drug pricing reform is likely to come in the net

Employers recently joined the chorus about drug pricing reform, calling for drastic changes. Recently, nearly 40 employer and health groups teamed, sending a letter to Congress calling for legislation to revamp drug pricing.

Aug 19, 2021

Some vaccine skeptics get vaccinated. What changed their mind?

A recent Kaiser Family Foundation survey suggests 3 reasons: (1) Seeing millions of Americans safely vaccinated, (2) Hearing the message from trusted experts, and (3) Learning that vaccination will open opportunities to participate in activities, like travel.

Aug 19, 2021

Patient and Payer Preferences for Additional Value Criteria

Real Endpoints President Susan Raiola contributed to this insightful piece on what payers and patients are looking for in additional value criteria. Payers, perhaps unsurprisingly, see value in treatments that provide tangible benefits, such as a addressing an unmet need. Patients, on the other hand, are looking towards the future, with an emphasis placed on the value of hope.